Welcome to our dedicated page for Zepp Health news (Ticker: ZEPP), a resource for investors and traders seeking the latest updates and insights on Zepp Health stock.
Zepp Health Corporation reports developments in smart wearables and health technology through its NYSE-listed ADRs. The company’s updates center on Amazfit smartwatches and fitness devices, including performance running, rugged outdoor and active-lifestyle product lines, as well as Zepp Clarity and Zepp Aura consumer health brands.
Recurring news themes include Amazfit product introductions, connected training features, biometric and recovery tools, Zepp OS and related platform technology, brand partnerships in fitness communities, unaudited financial results, share repurchase and debt-management commentary, and annual Form 20-F reporting for the foreign private issuer.
Zepp Health Corporation (NYSE: ZEPP) reported a robust 61.4% increase in revenue for Q2 2021, reaching RMB 1.8 billion (US$284.2 million). The company achieved a net income of RMB 92.6 million (US$14.3 million), significantly higher than last year’s RMB 13.3 million. Notably, Amazfit and Zepp branded product revenue surged 81%, while unit shipments increased 114%. The outlook for Q3 anticipates revenue between RMB 1.6 billion and RMB 1.8 billion, reflecting ongoing uncertainties from the COVID-19 pandemic.
Zepp Health Corp. (NYSE: ZEPP) announced it will report its second quarter 2021 financial results before market open on August 19, 2021. The management will host a conference call at 8:00 a.m. ET on the same day. Investors can access the call through various means including a toll-free US number. Zepp Health, formerly Huami Corp., focuses on cloud-based healthcare services and smart wearable technology, having shipped 46 million units in 2020, including 33 million smartwatches.
On July 27, 2021, Zepp Health Corp. (NYSE: ZEPP) announced a $2.4 million investment to lead a $6.5 million Series A funding round for neuro42, Inc.. This funding aims to advance MRI and robotics technology for diagnosing brain injuries and treating neurological diseases. neuro42 holds an exclusive license for low-field MR imaging technology associated with prestigious institutions. This marks Zepp’s third investment in medical imaging technologies, supporting its strategy to enhance health tech offerings, which includes previous success with FDA-cleared MRI technology for prostate interventions.
Amazfit, a brand of Zepp Health (NYSE: ZEPP), has launched the Amazfit PowerBuds Pro, true wireless earbuds equipped with advanced health monitoring and active noise cancellation. Key features include an industry-leading in-ear heart rate sensor, cervical spine angle detection, and smart hearing protection based on WHO standards. The earbuds offer multi-scenario noise cancellation up to 40dB, enhanced call quality with three microphones, and a battery life of up to 30 hours. Available for pre-order from July 15, they are priced at $149.99 in the US and €129.90 in Europe.
Zepp Health Corp. (NYSE: ZEPP) held its annual developer conference on July 13, 2021, unveiling significant advancements in wearable technology. The new Huangshan 2s chip enhances performance, reducing power consumption by 56% and improving graphics by 67%. Zepp OS, a lightweight operating system, promises improved energy efficiency and user experience. Additionally, the innovative PumpBeats™ technology enables non-invasive blood pressure monitoring. The company aims to integrate advanced medical imaging technologies, enhancing healthcare delivery.
Amazfit, a brand of Zepp Health (NYSE: ZEPP), is launching new true wireless stereo (TWS) earbuds with advanced health monitoring features. These earbuds include heart rate tracking and can detect head position to enhance posture, providing user feedback through an app. Additional features help monitor hearing health by analyzing volume and listening habits. Amazfit's innovative product aims to combine immersive audio technology with health tracking, meeting consumer needs in over 90 countries. The company significantly contributed to Zepp Health's growth, achieving top rankings in global smartwatch shipments.
Zepp Health Corp. (NYSE: ZEPP) announced that its Amazfit and Zepp products ranked among the top four in global shipments for Q1 2021, according to IDC data. The company experienced strong market positions, particularly in Brazil (40.9%), Russia (28.9%), and Spain (23.5%). Founded in 2013, Zepp Health focuses on integrating health and technology, developing AI-driven wearables. This announcement comes amid ongoing pandemic challenges, highlighting the brand's resilience and competitiveness in international markets.
Zepp Health Corp. (NYSE: ZEPP) reported Q1 2021 revenue of RMB1.1 billion (US$175.1 million), a 5.4% increase year-over-year. Despite a GAAP diluted net loss per share of RMB0.16 (US$0.02), self-branded Amazfit and Zepp product sales surged 84% year-over-year. The company expects strong performance in Q2 with anticipated net revenues between RMB1.7 billion and RMB1.8 billion, driven by ongoing demand for their products and new Xiaomi shipments. However, challenges from COVID-19 and increased operating costs persist.
Zepp Health Corp. (NYSE: ZEPP) will release its unaudited financial results for Q1 2021 before the market opens on May 13, 2021. A conference call is scheduled for 8:00 a.m. ET the same day, accessible via various dialing options listed in the release. The company, known for its smart healthcare technology and wearables, shipped 36.6 million units in 2019, holding a 23% share of global shipments for wearable devices. Investors can access live and archived webcasts from their investor relations page.
On April 21, 2021, Zepp Health Corp. (NYSE: ZEPP) announced the filing of its annual report on Form 20-F for the fiscal year ended December 31, 2020. The report highlights the company's achievements in the smart wearable technology space, which includes shipping 36.6 million units of smart watches and fitness bands in 2019, capturing 23% of global category shipments. Shareholders can access the report via the company's investor relations website and request hard copies free of charge.